scholarly journals Estimating human glioblastoma xenograft DCE-MRI response to Bevacizumab treatment

2020 ◽  
Vol 3 (1) ◽  
Author(s):  
Jesper Carl ◽  
Karsten Nielsen ◽  
Soeren Ravn
2014 ◽  
Vol 16 (5) ◽  
pp. 754-756 ◽  
Author(s):  
A. Pakzad ◽  
N. Obad ◽  
H. Espedal ◽  
D. Stieber ◽  
O. Keunen ◽  
...  

2012 ◽  
Vol 11 (4) ◽  
pp. 7290.2011.00050 ◽  
Author(s):  
Wei-Tsung Chen ◽  
Tiffany Ting Fang Shih ◽  
Ran-Chou Chen ◽  
Shin-Yang Tu ◽  
Hsieh Wen-Yuen ◽  
...  

The purpose of this study was to validate an integrin αvβ3–targeted magnetic resonance contrast agent, PEG-G3-(Gd-DTPA)6-(cRGD-DTPA)2, for its ability to detect tumor angiogenesis and assess early response to antiangiogenic therapy using dynamic contrast–enhanced (DCE) magnetic resonance imaging (MRI). Integrin αvβ3–positive U87 cells and control groups were incubated with fluorescein-labeled cRGD-conjugated dendrimer, and the cellular attachment of the dendrimer was observed. DCE MRI was performed on mice bearing KB xenograft tumors using either PEG-G3-(Gd-DTPA)6-(cRGD-DTPA)2 or PEG-G3-(Gd-DTPA)6-(cRAD-DTPA)2. DCE MRI was also performed 2 hours after anti–integrin αvβ3 monoclonal antibody treatment and after bevacizumab treatment on days 3 and 6t. Using DCE MRI, the 30-minute contrast washout percentage was significantly lower in the cRGD-conjugate injection groups. The enhancement patterns were different between the two contrast injection groups. In the antiangiogenic therapy groups, a rapid increase in 30-minute contrast washout percentage was observed in both the LM609 and bevacizumab treatment groups, and this occurred before there was an observable decrease in tumor size. The integrin αvβ3 targeting ability of PEG-G3-(Gd-DTPA)6-(cRGD-DTPA)2 in vitro and in vivo was demonstrated. The 30-minute contrast washout percentage is a useful parameter for examining tumor angiogenesis and for the early assessment of antiangiogenic treatment response.


2020 ◽  
Vol 52 (3) ◽  
pp. 850-863
Author(s):  
Ruiliang Bai ◽  
Bao Wang ◽  
Yinhang Jia ◽  
Zejun Wang ◽  
Charles S. Springer ◽  
...  

2020 ◽  
Author(s):  
H Meyer ◽  
G Hamerla ◽  
L Leifels ◽  
A Höhn ◽  
A Surov
Keyword(s):  

Sign in / Sign up

Export Citation Format

Share Document